目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T68672 | |||
Amsacrine lactate is an aminoacridine derivative with potential antineoplastic activity. Although its mechanism of action is incompletely defined, amsacrine may intercalate into DNA and inhibit topoisomerase II, resulting in DNA double-strand breaks, arrest of the S/G2 phase of the cell cycle, and cell death. | |||
T81962 | Monocarboxylate transporter | ||
Lactate transporter 1 (compound 1) 作为一种活性乳酸运输蛋白,主要在活细胞内发挥作用。在Hela、CAL27、MCF7和MCF10A细胞系中,Lactate transporter 1 均显示出了明显的毒性,其半抑制浓度(IC50)值依次为3.36、3.27、5.58和7.66 μM。此外,在HeLa细胞中,Lactate transporter 1 与Cisplatin表现出了协同抑制的作用。 | |||
T66299 | |||
Ciprofloxacin lactate 是一种有用的有机化合物,可用于生命科学领域的相关研究。其产品编号为 T66299,CAS号为 97867-33-9。 | |||
T70625 | |||
Nicotine is a naturally produced alkaloid in the nightshade family of plants (most predominantly in tobacco and Duboisia hopwoodii) and is widely used recreationally as a stimulant and anxiolytic. As a pharmaceutical drug, it is used for smoking cessation to relieve withdrawal symptoms. Nicotine acts as a receptor agonist at most nicotinic acetylcholine receptors (nAChRs), except at two nicotinic receptor subunits (nAChRα9 and nAChRα10) where it acts as a receptor antagonist. | |||
T76116 | |||
L-Lactate dehydrogenase (L-乳酸脱氢酶) 是一种氧化还原酶。L-Lactate dehydrogenase 在体内催化 NADH 将丙酮酸还原为 L-乳酸。 | |||
T76146 | |||
D-Lactate dehydrogenase(D-LDH)为一种氧化还原酶,以NAD+或NADP+作为受体,特异性作用于供体的CH-OH基团,催化D-乳酸氧化成丙酮酸。该酶主要分布于细菌和真菌中,是生化研究中常用的酶。 | |||
T5705 | Dehydrogenase | ||
Glomeratose A 是分离自远志Polygala tenuifolia 中,是一种乳酸脱氢酶lactate dehydrogenase 抑制剂。 | |||
T15435 | Dehydrogenase | ||
GSK2837808A 是一种选择性的乳酸脱氢酶A 抑制剂,对 hLDHA (IC50:2.6 nM) 和 hLDHB (IC50:43 nM)。 | |||
T11829 | Dehydrogenase | ||
LDH-IN-1 是新型的基于吡唑的人乳酸脱氢酶抑制剂,对于 LDHA 和 LDHB 的 IC50 分别为32和27 nM。 | |||
T22336 | Dehydrogenase | ||
Galloflavin 是乳酸脱氢酶抑制剂。用 Pyruvate 法得到的 Ki 为 5.46 µM (LDH-A) 以及15.06 µM (LDH-B)。它能够阻断 ATP 的生成和糖酵解,从而抑制癌细胞的增殖。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-04180 | PfLDH Protein, P. falciparum, Recombinant (His) | P. falciparum | E. coli | ||
Plasmodium falciparum lactate dehydrogenase (PfLDH) is a key enzyme for energy generation of malarial parasites and is considered to be a potential antimalarial target. The ability of PfLDH- or PfIDEh-based immuno-PCR assays to detect <1 parasite/microL suggests that improvements of bound antibody sensor technology may greatly increase the sensitivity of malaria rapid diagnostic tests. The PfLDH test could be used to detect failures and, therefore, to assess anti-malarial efficacy.
|
|||||
TMPY-04241 | LDHA Protein, Rat, Recombinant (His) | Rat | E. coli | ||
LDHA (Lactate Dehydrogenase A) is a Protein Coding gene. The protein encoded by this gene catalyzes the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. LDHA, a key enzyme regulating aerobic glycolysis, belongs to the lactate dehydrogenase family and is overexpressed in many human cancers, and correlates with poor clinical outcomes. LDHA can promote the Warburg effect to produce lactate and Adenosine Triphosphate (ATP) in aerobic conditions, which contributes to oncogenesis metastasis and drug resistance in various cancers. Up-regulation of lactate dehydrogenase LDHA is a frequent event in human malignancies and relate to poor postoperative outcome. Diseases associated with LDHA include Fanconi-Bickel Syndrome and Myoglobinuria.
|
|||||
TMPY-00010 | LDHA Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
LDHA (Lactate Dehydrogenase A) is a Protein Coding gene. The protein encoded by this gene catalyzes the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. LDHA, a key enzyme regulating aerobic glycolysis, belongs to the lactate dehydrogenase family and is overexpressed in many human cancers, and correlates with poor clinical outcomes. LDHA can promote the Warburg effect to produce lactate and Adenosine Triphosphate (ATP) in aerobic conditions, which contributes to oncogenesis metastasis and drug resistance in various cancers. Up-regulation of lactate dehydrogenase LDHA is a frequent event in human malignancies and relate to poor postoperative outcome. Diseases associated with LDHA include Fanconi-Bickel Syndrome and Myoglobinuria.
|
|||||
TMPJ-00797 | LDHB Protein, Human, Recombinant (His) | Human | E. coli | ||
L-Lactate Dehydrogenase B Chain (LDH-B) is a member of the lactate dehydrogenase family that consists of three members, LDH-A, LDH-B and LDH-C; members of this family function as powerful markers for germ cell tumors. LDH-B is an oxidoreductase that catalyzes the interconversion of pyruvate and lactate with concomitant interconversion of NADH and NAD+. It converts pyruvate to lactate when oxygen is absent or in short supply and it performs the reverse reaction during the Cori cycle in the liver. It is also called Hydroxybutyrate Dehydrogenase (HBD) due to its ability to catalyze the oxidation of hydroxybutyrate.
|
|||||
TMPH-03136 | L-lactate dehydrogenase Protein, Plasmodium berghei, Recombinant (His & Myc) | Plasmodium berghei | E. coli | ||
L-lactate dehydrogenase Protein, Plasmodium berghei, Recombinant (His & Myc) is expressed in E. coli.
|
|||||
TMPJ-00724 | LDHA Protein, Human, Recombinant (His) | Human | E. coli | ||
L-Lactate Dehydrogenase A Chain (LDHA) is an enzyme that catalyzes the conversion of L-lactate and NAD+ to pyruvate and NADH in the final step of anaerobic glycolysis. LDHA contains an N-terminal coenzyme binding region, a central catalytic site, and at least nine utilized Lys acetylation and two Tyr phosphorylation sites. LDHA belongs to the lactate dehydrogenase family, expressed predominantly in muscle tissue. LDHA mutations have been linked to exertional myoglobinuria.
|
|||||
TMPH-00693 | L-lactate dehydrogenase Protein, E. coli O9:H4, Recombinant (His) | E. coli | E. coli | ||
Catalyzes the conversion of L-lactate to pyruvate. Is coupled to the respiratory chain.
|
|||||
TMPY-04826 | LILRB5/CD85c Protein, Human, Recombinant (His) | Human | HEK293 | ||
A genetic variant in LILRB5 (leukocyte immunoglobulin-like receptor subfamily-B) (rs12975366: T > C: Asp247Gly) has been reported to be associated with lower creatine phosphokinase (CK) and lactate dehydrogenase (LDH) levels. Both biomarkers are released from injured muscle tissue, making this variant a potential candidate for susceptibility to muscle-related symptoms.
|
|||||
TMPH-01696 | SLC16A4 Protein, Human, Recombinant (His) | Human | E. coli | ||
Proton-linked monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate.
|
|||||
TMPY-05186 | LILRB5/CD85c Protein, Human, Recombinant (His), Biotinylated | Human | HEK293 | ||
A genetic variant in LILRB5 (leukocyte immunoglobulin-like receptor subfamily-B) (rs12975366: T > C: Asp247Gly) has been reported to be associated with lower creatine phosphokinase (CK) and lactate dehydrogenase (LDH) levels. Both biomarkers are released from injured muscle tissue, making this variant a potential candidate for susceptibility to muscle-related symptoms.
|
|||||
TMPY-06273 | LILRB5/CD85c Protein, Human, Recombinant (hFc) | Human | HEK293 | ||
A genetic variant in LILRB5 (leukocyte immunoglobulin-like receptor subfamily-B) (rs12975366: T > C: Asp247Gly) has been reported to be associated with lower creatine phosphokinase (CK) and lactate dehydrogenase (LDH) levels. Both biomarkers are released from injured muscle tissue, making this variant a potential candidate for susceptibility to muscle-related symptoms.
|
|||||
TMPH-01202 | D2HGDH Protein, Human, Recombinant (His & SUMO) | Human | E. coli | ||
Catalyzes the oxidation of D-2-hydroxyglutarate (D-2-HG) to alpha-ketoglutarate. Also catalyzes the oxidation of other D-2-hydroxyacids, such as D-malate (D-MAL) and D-lactate (D-LAC). Exhibits high activities towards D-2-HG and D-MAL but a very weak activity towards D-LAC.
|
|||||
TMPY-02288 | Glyoxalase II/HAGH Protein, Human, Recombinant (His) | Human | E. coli | ||
HAGH (Hydroxyacylglutathione Hydrolase) is a Protein Coding gene. 3 alternative splicing and alternative initiation of human isoforms have been reported. The enzyme encoded by this gene is classified as a thioesterase and is responsible for the hydrolysis of S-lactoyl-glutathione to reduced glutathione and D-lactate. HAGH belongs to the Metallo-beta-lactamase superfamily. HAGH is widely expressed in the kidney, liver, and other tissues. Diseases associated with HAGH include Hydroxyacyl Glutathione Hydrolase Deficiency. Among its related pathways are Pyruvate metabolism and Citric Acid (TCA) cycle and Metabolism. The human and rodent forms of glyoxalase II (HAGH) can readily be separated by starch gel electrophoretic procedures.
|
|||||
TMPH-01860 | PCK1 Protein, Human, Recombinant (His) | Human | E. coli | ||
Cytosolic phosphoenolpyruvate carboxykinase that catalyzes the reversible decarboxylation and phosphorylation of oxaloacetate (OAA) and acts as the rate-limiting enzyme in gluconeogenesis. Regulates cataplerosis and anaplerosis, the processes that control the levels of metabolic intermediates in the citric acid cycle. At low glucose levels, it catalyzes the cataplerotic conversion of oxaloacetate to phosphoenolpyruvate (PEP), the rate-limiting step in the metabolic pathway that produces glucose from lactate and other precursors derived from the citric acid cycle. At high glucose levels, it catalyzes the anaplerotic conversion of phosphoenolpyruvate to oxaloacetate. Acts as a regulator of formation and maintenance of memory CD8(+) T-cells: up-regulated in these cells, where it generates phosphoenolpyruvate, via gluconeogenesis. The resultant phosphoenolpyruvate flows to glycogen and pentose phosphate pathway, which is essential for memory CD8(+) T-cells homeostasis. In addition to the phosphoenolpyruvate carboxykinase activity, also acts as a protein kinase when phosphorylated at Ser-90: phosphorylation at Ser-90 by AKT1 reduces the binding affinity to oxaloacetate and promotes an atypical serine protein kinase activity using GTP as donor. The protein kinase activity regulates lipogenesis: upon phosphorylation at Ser-90, translocates to the endoplasmic reticulum and catalyzes phosphorylation of INSIG proteins (INSIG1 and INSIG2), thereby disrupting the interaction between INSIG proteins and SCAP and promoting nuclear translocation of SREBP proteins (SREBF1/SREBP1 or SREBF2/SREBP2) and subsequent transcription of downstream lipogenesis-related genes.
|